This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

The Food and Drug Administration gave Pfizer's (PFE - Get Report) HIV drug its blessing Monday while rumors of good data lifted another health stock.

The FDA granted accelerated approval to Pfizer's Selzentry tablets for HIV based on 24-week data. The drug is the first in a class (called CCR5 antagonists) that stop the R5 virus on the outside surface of cells before it enters, rather than fighting the virus inside as do all other classes of oral HIV medicines, according the company.

"The approval of Selzentry for treatment-experienced patients is a significant breakthrough, and we continue its development in a spectrum of other patients living with HIV/AIDS," said Joseph Feczko, Pfizer's chief medical officer. Selzentry is expected to be available in the U.S. by the middle of September. The company recently received a positive opinion from the Committee for Medicinal Products for Human Use in the EU, and plans to commercialize it as Celsentri outside of the U.S. The stock was up 54 cents, or 2.3%, at $24.05.

Vertex Pharmaceuticals (VRTX - Get Report) gained $2.92, or 8.8%, to $36.14 after analysts at Leerink Swann & Co. issued a note indicating a favorable outlook for interim data from the PROVE-1 study of Telaprevir in Hepatitis C patients. The analysts also said that management comments suggest the key clinical data from PROVE-1 will be presented at the American Association for the Study of Liver Diseases meeting in November and not the Interscience Conference on Antimicrobial Agents and Chemotherapy in September.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ACAD $41.68 0.31%
ARIA $8.94 -0.33%
PFE $34.38 -0.30%
VRTX $125.75 0.76%
AAPL $130.41 0.35%

Markets

DOW 18,106.60 +94.66 0.53%
S&P 500 2,118.82 +9.22 0.44%
NASDAQ 5,107.6630 +31.1390 0.61%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs